Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years

Trial Profile

Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Ecopipam (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Therapeutic Use
  • Sponsors Psyadon Pharmaceuticals
  • Most Recent Events

    • 08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
    • 04 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
    • 04 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top